Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Abeona Therapeutics (ABEO) EBIT Margin (2016 - 2025)

Abeona Therapeutics (ABEO) has 13 years of EBIT Margin data on record, last reported at 5698.0% in Q2 2025.

  • For Q2 2025, EBIT Margin changed N/A year-over-year to 5698.0%; the TTM value through Sep 2025 reached 20802.25%, changed N/A, while the annual FY2023 figure was 1346.71%, 225406.0% up from the prior year.
  • EBIT Margin reached 5698.0% in Q2 2025 per ABEO's latest filing, down from 301.54% in the prior quarter.
  • Across five years, EBIT Margin topped out at 88022.64% in Q4 2021 and bottomed at 19023.53% in Q4 2022.
  • Average EBIT Margin over 4 years is 6709.99%, with a median of 301.54% recorded in 2023.
  • Peak YoY movement for EBIT Margin: skyrocketed 8871401bps in 2021, then tumbled -10704617bps in 2022.
  • A 4-year view of EBIT Margin shows it stood at 88022.64% in 2021, then crashed by -122bps to 19023.53% in 2022, then soared by 98bps to 301.54% in 2023, then plummeted by -1790bps to 5698.0% in 2025.
  • Per Business Quant database, its latest 3 readings for EBIT Margin were 5698.0% in Q2 2025, 301.54% in Q2 2023, and 19023.53% in Q4 2022.